joshua0111
2021-07-22
Nice
Here's Why Cassava Sciences Is Surging Today
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":172978116,"tweetId":"172978116","gmtCreate":1626931292135,"gmtModify":1633769604902,"author":{"id":3579878222573636,"idStr":"3579878222573636","authorId":3579878222573636,"authorIdStr":"3579878222573636","name":"joshua0111","avatar":"https://static.tigerbbs.com/662a143659b3954c78c2e0a2c91c466b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/172978116","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","kind":"news","pubTimestamp":1626926115,"share":"https://www.laohu8.com/m/news/1146624774?lang=&edition=full","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8 <a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/172978116"}
精彩评论